ArticleEJNMMI research2016
Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease.
Article in EJNMMI research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease.Journal of neuroinflammation · 2025Trial
- Network-based disease fingerprinting with neuroinflammation PET imaging.Journal of neuroinflammation · 2026Article
- Network-based disease fingerprinting with neuroinflammation PET imaging.Research square · 2025Article
- Clinical heterogeneity of neuro-inflammatory PET profiles in early Alzheimer's disease.Frontiers in neurology · 2023Article
- Brain microglia activation and peripheral adaptive immunity in Parkinson's disease: a multimodal PET study.Journal of neuroinflammation · 2022Article
- Tracers progress for positron emission tomography imaging of glial-related disease.Journal of biomedical research · 2022Article
- Impact of 40 Hz Transcranial Alternating Current Stimulation on Cerebral Tau Burden in Patients with Alzheimer's Disease: A Case Series.Journal of Alzheimer's disease : JAD · 2022Article
- Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: AnFrontiers in neurology · 2020Article
- Association of neuroinflammation with episodic memory: a [Brain communications · 2020Article
- Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains.Annals of clinical and translational neurology · 2019Article
- Automatic Extraction of a Reference Region for the Noninvasive Quantification of Translocator Protein in Brain UsingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31.Human molecular genetics · 2018Article
- Parametric mapping using spectral analysis forEuropean journal of nuclear medicine and molecular imaging · 2018Article
- Article
- In vivo PET imaging of neuroinflammation in Alzheimer's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Imaging of glia activation in people with primary lateral sclerosis.NeuroImage. Clinical · 2018Article
- Assessment of simplified ratio-based approaches for quantification of PET [EJNMMI research · 2017Article
- Erratum to: Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease.EJNMMI research · 2017Article
- Effect of Cigarette Smoking on a Marker for Neuroinflammation: A [Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Article
- The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory 'M1' human macrophages.PloS one · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
purposeIn order to maximise the utility of [(11)C]-PBR28 for use in longitudinal studies and clinical trials in Alzheimer's disease (AD), there is a need to develop non-invasive metrics of tracer binding that do not require arterial cannulation. Recent work has suggested that standardised uptake value (SUV)-based methods may be sensitive to changes in translocator protein (TSPO) levels associated with neurodegeneration. However, the test-retest reliability of these approaches in AD over a time period relevant for clinical trials is unknown. In this study, the test-retest reliability of three SUV-based metrics was assessed in AD patients over 12 weeks.
methodsFive patients with mild AD and the high-affinity binding TSPO genotype underwent two [(11)C]-PBR28 PET scans approximately 12 weeks apart. The test-retest reliability (TRR) of the unadjusted SUV, SUV relative to cerebellar grey matter (SUVRC) and SUV normalised to whole brain activity (SUVRWB) in nine cortical and limbic regions of interest was assessed using the absolute variability and the intraclass correlation coefficient.
resultsOf the three measures, SUVRWB performed best overall, showing low absolute variability (mean -0.13 %, SD 2.47 %) and high reliability (mean ICC = 0.83). Unadjusted SUV also performed well, with high reliability (ICC = 0.94) but also high variability (mean -1.24 %, SD 7.28 %). By comparison, the SUVRC showed higher variability (mean -3.98 %, SD 7.07 %) and low reliability (ICC = 0.65).
conclusionsIn this AD sample, we found that SUV-derived metrics of [(11)C]-PBR28 binding showed high stability over 12 weeks. These results compare favourably with studies reporting TRR of absolute quantification of [(11)C]-PBR28. Pending further validation of SUV-based measures of [(11)C]-PBR28, semi-quantitative methods of [(11)C]-PBR28 analysis may prove useful in longitudinal studies of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.